-
61.发明授权
公开(公告)号：KR101581508B1
公开(公告)日：2015-12-31
申请号：KR1020130149463
申请日：2013-12-03
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/122 , A61K9/127 , A61P19/02
Abstract: 본발명은코엔자임 Q10을유효성분으로포함하는염증성질환또는면역거부질환의예방또는치료용조성물에관한것으로서, 보다구체적으로본 발명의코엔자임 Q10(coenzyme Q10)은 Th17의활성을억제또는감소시키고, 조절 T 세포(Regulatory T cell: Treg)의활성을촉진또는증가시키는효과가우수하여, 이식거부질환과같은면역거부질환또 는염증성질환을예방또는치료할수 있는조성물로유용하게사용할수 있다. 또한, 세포독성이일어나지않으며, 약물에대한독성및 부작용도없어장기간복용시에도안심하고사용할수 있으며, 체내에서도안정한효과가있다. 또한본 발명은면역거부질환의예방또는치료용조성물에관한것으로서, 보다구체적으로본 발명은리포좀형태의코엔자임 Q10(coenzyme Q10) 및 FK-506 화합물을유효성분으로포함하는면역거부질환의예방또는치료용조성물및 리포좀형태의코엔자임 Q10(coenzyme Q10)을제조하는방법에관한것이다. 본발명에서제공하는리포좀형태의코엔자임 Q10(coenzyme Q10) 및 FK-506 화합물을유효성분으로포함하는면역거부질환의예방또는치료용조성물은종래코엔자임 Q10(coenzyme Q10)의불용성문제및 안정성문제를해결하여코엔자임 Q10이가지고있는약리학적효과를극대화시킬수 있고, FK-506 화합물과병용처리함으로써상기 FK-506 화합물이갖는부작용을최소화시킬수 있으므로, 이식거부질환과같은면역거부질환을매우효과적으로예방또는치료할수 있고, 세포독성을유발시키지않아약물에대한독성및 부작용도없어장기간복용시에도안심하고사용할수 있는효과가있다.
-
公开(公告)号：KR101580389B1
公开(公告)日：2015-12-28
申请号：KR1020140035282
申请日：2014-03-26
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K31/122 , A61P29/00 , A61P37/00
Abstract: 본발명은면역반응의이상으로유발되는면역질환을예방또는치료하는데사용되는메트포민과코엔자임 Q10을유효성분으로함유하는면역질환의예방또는치료용조성물에관한것이다. 본발명에따른메트포민과코엔자임 Q10의병용투여는염증성사이토카인인 TNF-a, IL-6, IL-17, IFN-γ및/또는 IL-1b의발현을억제시키는효과가있고, 관절염유도동물모델에서파골세포분화를감소시키거나, 염증성세포의침윤을억제시키는효과가있다. 또한, 본발명의조성물은염증성장 질환으로야기되는몸무게감소를개선하는효과를가지고있고, 병인 B 세포의 IgG의활성을조절하는효과를가지고있으며, 염증성사이토카인의발현을억제시키고, Foxp3+ Treg의활성을증진시키는효과가우수한바, 염증성장 질환, 루푸스, 이식편대숙주병등의다양한면역질환의예방또는치료용조성물로유용하게활용가능할것이다.
-
63.发明公开바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물 有权用于预防或治疗包含BIGUANIDE衍生化合物的免疫缺陷病毒或炎症性疾病的药物组合物
公开(公告)号：KR1020150022731A
公开(公告)日：2015-03-04
申请号：KR1020140110919
申请日：2014-08-25
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K31/36 , A61P29/00
CPC classification number: A61K31/155 , A61K2121/00 , A61K2300/00 , C07C279/18 , C07C279/26
Abstract: 본 발명은 면역질환을 효과적으로 예방 및 치료할 수 있는 바이구아나이드(biguanide) 유도체 화합물에 관한 것이다. 본 발명의 바이구아나이드계 유도체 화합물은 염증성 사이토카인인 IL-17 및 TNF-α의 생성을 억제시키며, 면역조절 기능을 갖는 조절 T 세포의 활성을 증대시킬 뿐만 아니라, 면역질환 동물모델에 대해 우수한 치료 효과를 나타낸다. 따라서 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 또는 치료할 수 있는 약학적 조성물 또는 면역 억제제로 유용하게 사용될 수 있다.
Abstract translation: 本发明涉及能够有效预防和治疗免疫疾病的双胍衍生物。 本发明的双胍衍生化合物抑制作为炎症细胞因子的IL-17和TNF-α的产生，增加具有免疫调节功能的调节性T细胞的活性，并且在具有免疫疾病的动物模型中表现出优异的治疗效果 。 因此，双胍类衍生化合物可以有利地用作免疫抑制剂或能够预防或治疗由免疫应答失调引起的各种免疫疾病如自身免疫性疾病，炎性疾病和移植排斥的药物组合物。
-
公开(公告)号：KR1020140036598A
公开(公告)日：2014-03-26
申请号：KR1020120102887
申请日：2012-09-17
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61P37/00
CPC classification number: A61K31/155
Abstract: The present invention relates to a composition for preventing or treating immune diseases by suppressing B cell activities which are induced by metformin and, more specifically, to a composition for preventing or treating immune diseases, which includes a metformin compound or pharmaceutically acceptable salts thereof. The composition suppresses or reduces activities of etiological B cells. According to the present invention, the composition for preventing or treating immune diseases can be used as an immune suppressor by suppressing or reducing the etiological B cells in various autoimmune diseases, suppressing or reducing activities of etiological Th17 cells, and promoting or increasing activities of regulatory T cells (Treg).
Abstract translation: 本发明涉及通过抑制二甲双胍诱导的B细胞活性，更具体地说，涉及包含二甲双胍化合物或其药学上可接受的盐的免疫疾病的预防或治疗组合物，用于预防或治疗免疫疾病的组合物。 该组合物抑制或减少病原B细胞的活性。 根据本发明，用于预防或治疗免疫疾病的组合物可以通过抑制或减少各种自身免疫疾病中的病原B细胞，抑制或减少病原Th17细胞的活性，以及促进或增加调节活性 T细胞（Treg）。
-
公开(公告)号：KR1020130111448A
公开(公告)日：2013-10-10
申请号：KR1020130034471
申请日：2013-03-29
Applicant: 가톨릭대학교 산학협력단
IPC: C12N15/861 , A61K35/12 , A61P37/00
Abstract: PURPOSE: A composition containing mesenchymal stem cells for treating autoimmune diseases is provided to improve immunity and to prevent dermatitis which is a side effect of a steroid formulation, thereby being used as a safety therapeutic agent for treating autoimmune diseases. CONSTITUTION: A composition for treating autoimmune diseases contains mesenchymal stem cells. The composition treats autoimmune diseases by promoting the generation or activation of regulatory B cells or suppressing the generation of antibody producing B cells. The regulatory B cells are B reg or B10 cells. The B cells are CD19+CD1d+CD5+ B cells or marginal zone B cells.
Abstract translation: 目的：提供一种含有间充质干细胞用于治疗自身免疫性疾病的组合物，用于提高免疫力，防止作为类固醇制剂的副作用的皮炎，从而用作治疗自身免疫疾病的安全治疗剂。 构成：用于治疗自身免疫性疾病的组合物含有间充质干细胞。 组合物通过促进调节性B细胞的产生或活化或抑制产生抗体的B细胞来治疗自身免疫性疾病。 调节性B细胞是B reg或B10细胞。 B细胞是CD19 + CD1d + CD5 + B细胞或边缘区B细胞。
-
Patent Agency Ranking66.发明公开
公开(公告)号：KR1020130106320A
公开(公告)日：2013-09-27
申请号：KR1020130028981
申请日：2013-03-19
Applicant: 가톨릭대학교 산학협력단
Abstract: PURPOSE: A composition containing myeloid derived suppressor cells as active ingredients for preventing or treating transplant rejection or autoimmune diseases is provided to promote generation of regulatory B cells and activation of antibody-producing B cells, thereby treating immune diseases including autoimmune diseases. CONSTITUTION: A composition for preventing or treating transplant rejection or autoimmune diseases contains myeloid derived suppressor cells. Myeloid derived suppressor cells are isolated and differentiated from bone marrow of an individual with immune diseases. The composition promotes generation of regulatory B cells or suppresses activation of antibody-producing B cells. Myeloid derived suppressor cells are differentiated by GM-CSF or M-CSF. Myeloid derived suppressor cells have CD11b^+Gr-1^+ marker by induction of differentiation.
Abstract translation: 目的：提供含有骨髓来源的抑制细胞作为预防或治疗移植排斥反应或自身免疫性疾病的活性成分的组合物，以促进调节性B细胞的产生和产生抗体的B细胞的活化，从而治疗包括自身免疫疾病在内的免疫疾病。 构成：用于预防或治疗移植排斥反应或自身免疫性疾病的组合物含有骨髓来源的抑制细胞。 骨髓来源的抑制细胞被分离并与具有免疫疾病的个体的骨髓分化。 该组合物促进调节性B细胞的产生或抑制产生抗体的B细胞的活化。 髓系衍生的抑制细胞被GM-CSF或M-CSF分化。 骨髓衍生抑制细胞通过诱导分化具有CD11b ^ + Gr-1 ^ +标记。
-
67.发明公开간엽줄기세포 및 ⅠＬ-21 차단제를 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물 有权用于预防或治疗包含MESENCHYMAL STEM细胞和IL-21抑制剂的GRAFT-VERSUS-HOST疾病的组合物
公开(公告)号：KR1020130032465A
公开(公告)日：2013-04-02
申请号：KR1020110096057
申请日：2011-09-23
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K48/00 , A61K35/28 , A61K48/005 , A61K48/0075
Abstract: PURPOSE: A cell therapeutic composition is provided to effectively suppress immune rejection from a transplant process, and to prevent or treat graft-versus-host disease. CONSTITUTION: A pharmaceutical composition for preventing or treating graft-versus-host disease contains 1ug/ul-3ug/ul of genes which suppresses an IL-21 receptor and 2x10^5-2x10^7 mesenchymal stem cells as an active ingredient. The mesenchymal stem cells are derived from human.
Abstract translation: 目的：提供细胞治疗组合物以有效抑制移植过程的免疫排斥，并预防或治疗移植物抗宿主病。 构成：用于预防或治疗移植物抗宿主病的药物组合物含有1ug / ul-3ug / ul的基因，其抑制IL-21受体和2×10 ^ 5-2×10 ^ 7间充质干细胞作为活性成分。 间充质干细胞来源于人。
-
公开(公告)号：KR1020120029342A
公开(公告)日：2012-03-26
申请号：KR1020110092596
申请日：2011-09-14
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/225 , A61K31/21 , A61P35/00
Abstract: PURPOSE: A composition containing retinal for preventing or treating cancer or immune diseases is provided to enhance immune-modulating T cell activity. CONSTITUTION: A composition for preventing or treating cancer or immune disease contains retinal compounds of pharmaceutically acceptable salt thereof as an active ingredient. The retinal promotes or enhances regulatory T cell activity or proliferation. A method for reducing or suppressing differentiation of immature T cell into Th17 cell in vitro comprises a step of treating retinal compound or pharmaceutically acceptable salt to the undifferentiated T cells.
Abstract translation: 目的：提供含有用于预防或治疗癌症或免疫疾病的视网膜的组合物，以增强免疫调节T细胞活性。 构成：用于预防或治疗癌症或免疫疾病的组合物含有其药学上可接受的盐的视黄醛化合物作为活性成分。 视网膜促进或增强调节性T细胞活性或增殖。 用于在体外降低或抑制未成熟T细胞分化成Th17细胞的方法包括将视黄醛化合物或药学上可接受的盐处理至未分化的T细胞的步骤。
-
公开(公告)号：KR1020110044490A
公开(公告)日：2011-04-29
申请号：KR1020090101194
申请日：2009-10-23
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C07K14/495 , A61K35/28 , A61K38/00 , C12N5/0663 , C12N2501/15 , C12N2510/00 , A61K48/00 , C12N15/10 , A61K2300/00
Abstract: PURPOSE: A mesenchymsal stem cells and a composition containing the same for treating autoimmune diseases are provided to enhance autoantigen-specific CD4+ CD25+ Foxp3+ regulatory T cells and to treat autoimmune diseases. CONSTITUTION: A composition for treating autoimmune diseases contains mesenchymal stem cells in which TFG-beta-encoding nucleotide sequence is introduced and pharmaceutically acceptable carrier. The TGF-beta-encoding nucleotide sequence is sequence number 2. The TGF-beta-encoding nucleotide sequence is introduced by adenovirus-associated vector. The mesenchymal stem cell is derived from bone marrow-derived mesenchymal stem cells or adipose-derived mesenchymal stem cells.
Abstract translation: 目的：提供间充质干细胞和含有其的用于治疗自身免疫性疾病的组合物，以增强自身抗原特异性CD4 + CD25 + Foxp3 +调节性T细胞并治疗自身免疫性疾病。 构成：用于治疗自身免疫性疾病的组合物含有引入TFG-β编码核苷酸序列的间充质干细胞和药学上可接受的载体。 TGF-β编码核苷酸序列是序列号2.由腺病毒相关载体引入TGF-β编码的核苷酸序列。 间充质干细胞衍生自骨髓间充质干细胞或脂肪来源的间充质干细胞。
-
公开(公告)号：KR1020210033450A
公开(公告)日：2021-03-26
申请号：KR1020210034472
申请日：2021-03-17
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은골수유래억제세포(MDSC, myeloid-derived suppressor cells) 및조절 T 세포(regulatory T cell, Treg)를유효성분으로포함하는면역조절용약학적조성물및 이의다양한적용에관한것이다. 본발명의조성물은 Foxp3+Treg 세포및IL-10 유도한 CD1d+CD5+ Breg 세포를증가시키고, IL-17+CD4+T 세포를억제시킴을확인였는바, MDSC 및 Treg의병용처리는각 단독처리보다시너지효과가나타나유의적인면역조절능이존재함을확인하였다. 또한, 상기시너지효과로인하여, 쇼그렌증후군및 이식편대숙주병에유의적인치료효과가확인되어, 관련약학및 식품산업에유용하게이용될수 있다.
-
-
-
-
-
-
-
-
-
Search Results
104
records
(took 0.039 seconds)
